Published in Endocr Relat Cancer on December 16, 2013
SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3. Oncotarget (2015) 0.97
Structure and function of SET and MYND domain-containing proteins. Int J Mol Sci (2015) 0.91
Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential. J Cell Mol Med (2014) 0.90
A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases. ACS Chem Biol (2015) 0.87
A gain-of-function mouse model identifies PRMT6 as a NF-κB coactivator. Nucleic Acids Res (2014) 0.86
Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound. ACS Med Chem Lett (2015) 0.85
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor. ACS Med Chem Lett (2015) 0.81
A Common Variant in the SETD7 Gene Predicts Serum Lycopene Concentrations. Nutrients (2016) 0.79
Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6. J Med Chem (2016) 0.78
Inhibitors of Protein Methyltransferases and Demethylases. Chem Rev (2017) 0.76
KDM4A, KDM4B and KDM4C in non-small cell lung cancer. Int J Clin Exp Pathol (2015) 0.76
Epigenetic modulators as therapeutic targets in prostate cancer. Clin Epigenetics (2016) 0.76
Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers (Basel) (2017) 0.75
Epigenetic therapy in urologic cancers: an update on clinical trials. Oncotarget (2016) 0.75
Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer Treatment. Clin Cancer Res (2016) 0.75
Protein Arginine Methyltransferase 6 Involved in Germ Cell Viability during Spermatogenesis and Down-Regulated by the Androgen Receptor. Int J Mol Sci (2015) 0.75
Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer. Oncotarget (2016) 0.75
Androgen receptor regulation by histone Methyltransferase suppressor of variegation 3-9 homolog 2 and melanoma antigen-A11. Mol Cell Endocrinol (2016) 0.75
TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia (2006) 2.48
Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. Eur Urol (2006) 2.19
A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res (2004) 2.06
Acute ketamine impairs mitochondrial function and promotes superoxide dismutase activity in the rat brain. Anesth Analg (2015) 2.03
Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res (2002) 1.88
Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol (2005) 1.80
The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum Mutat (2013) 1.78
Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res (2004) 1.76
Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl) (2006) 1.72
Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70
Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res (2010) 1.62
Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.62
Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol (2011) 1.49
P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res (2005) 1.36
High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res (2007) 1.30
Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro. J Exp Clin Cancer Res (2012) 1.28
BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol (2004) 1.27
Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res (2011) 1.23
Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res (2006) 1.22
Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate (2004) 1.20
TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics (2011) 1.20
MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.18
FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes Cancer (2011) 1.17
Human cancer cell antiproliferative and antioxidant activities of Juglans regia L. Food Chem Toxicol (2009) 1.14
Obesity and prostate cancer: gene expression signature of human periprostatic adipose tissue. BMC Med (2012) 1.13
Access control: how can it improve patients' healthcare? Stud Health Technol Inform (2007) 1.11
Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology (2002) 1.11
8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res (2006) 1.11
Epigenetic biomarkers in urological tumors: A systematic review. Cancer Lett (2011) 1.09
Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res (2006) 1.09
Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer (2007) 1.06
Comparison of anesthetic depth indexes based on thalamocortical local field potentials in rats. Anesthesiology (2010) 1.06
Regular physical exercise as a strategy to improve antioxidant and anti-inflammatory status: benefits in type 2 diabetes mellitus. Oxid Med Cell Longev (2012) 1.06
Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes Cancer (2006) 1.04
Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance. Clin Cancer Res (2011) 1.04
Biallelic inactivation of the RIZ1 gene in human gastric cancer. Oncogene (2003) 1.04
Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia (2012) 1.03
Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res (2003) 1.03
Biological activities of Portuguese propolis: protection against free radical-induced erythrocyte damage and inhibition of human renal cancer cell growth in vitro. Food Chem Toxicol (2010) 1.01
Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol (2004) 1.01
I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2002) 1.00
Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics (2010) 0.99
Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Res Treat (2007) 0.99
Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer. Prostate (2008) 0.98
Epigenetic markers for molecular detection of prostate cancer. Dis Markers (2007) 0.96
Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol Oncol Res (2011) 0.96
Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. Cancer Genet (2011) 0.95
Regulation of histone H2A.Z expression is mediated by sirtuin 1 in prostate cancer. Oncotarget (2013) 0.95
Expression and functionality of histone H2A variants in cancer. Oncotarget (2014) 0.95
Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer. Genes Chromosomes Cancer (2011) 0.95
Metabolic susceptibility genes and prostate cancer risk in a southern European population: the role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms. Prostate (2004) 0.94
Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. BMC Cancer (2010) 0.94
MSI phenotype and MMR alterations in familial and sporadic gastric cancer. Int J Cancer (2010) 0.94
Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. PLoS One (2011) 0.94
A clinical case of Castleman's disease. J Thorac Oncol (2007) 0.94
Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer. BMC Genomics (2013) 0.93
High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. BMC Cancer (2013) 0.93
Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions. DNA Cell Biol (2005) 0.93
Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate (2002) 0.93
Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence. Innate Immun (2012) 0.92
A rapid and simple procedure for the establishment of human normal and cancer renal primary cell cultures from surgical specimens. PLoS One (2011) 0.92
The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. J Hum Genet (2002) 0.92
High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. Breast Cancer Res Treat (2010) 0.91
Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer (2003) 0.91